Pharmacokinetic Analysis of 64Cu-ATSM Dynamic PET in Human Xenograft Tumors in Mice

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Pharmacokinetic Analysis of 64Cu-ATSM Dynamic PET in Human Xenograft Tumors in Mice. / Li, Fan; Jørgensen, Jesper Tranekjær; Madsen, Jacob; Kjaer, Andreas.

I: Diagnostics, Bind 5, Nr. 2, 27.03.2015, s. 96-112.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Li, F, Jørgensen, JT, Madsen, J & Kjaer, A 2015, 'Pharmacokinetic Analysis of 64Cu-ATSM Dynamic PET in Human Xenograft Tumors in Mice', Diagnostics, bind 5, nr. 2, s. 96-112. https://doi.org/10.3390/diagnostics5020096

APA

Li, F., Jørgensen, J. T., Madsen, J., & Kjaer, A. (2015). Pharmacokinetic Analysis of 64Cu-ATSM Dynamic PET in Human Xenograft Tumors in Mice. Diagnostics, 5(2), 96-112. https://doi.org/10.3390/diagnostics5020096

Vancouver

Li F, Jørgensen JT, Madsen J, Kjaer A. Pharmacokinetic Analysis of 64Cu-ATSM Dynamic PET in Human Xenograft Tumors in Mice. Diagnostics. 2015 mar. 27;5(2):96-112. https://doi.org/10.3390/diagnostics5020096

Author

Li, Fan ; Jørgensen, Jesper Tranekjær ; Madsen, Jacob ; Kjaer, Andreas. / Pharmacokinetic Analysis of 64Cu-ATSM Dynamic PET in Human Xenograft Tumors in Mice. I: Diagnostics. 2015 ; Bind 5, Nr. 2. s. 96-112.

Bibtex

@article{468f1de9f0444fc990c6f846f1f1e139,
title = "Pharmacokinetic Analysis of 64Cu-ATSM Dynamic PET in Human Xenograft Tumors in Mice",
abstract = "The aim of this study was to evaluate the feasibility to perform voxel-wise kinetic modeling on datasets obtained from tumor-bearing mice that underwent dynamic PET scans with 64Cu-ATSM and extract useful physiological parameters.METHODS: Tumor-bearing mice underwent 90-min dynamic PET scans with 64Cu-ATSM and CT scans with contrast. Irreversible and reversible two-tissue compartment models were fitted to time activity curves (TACs) obtained from whole tumor volumes and compared using the Akaike information criterion (AIC). Based on voxel-wise pharmacokinetic analysis, parametric maps of model rate constants k₁, k₃ and Ki were generated and compared to 64Cu-ATSM uptake.RESULTS: Based on the AIC, an irreversible two-tissue compartment model was selected for voxel-wise pharmacokinetic analysis. Of the extracted parameters, k₁ (~perfusion) showed a strong correlation with early tracer uptake (mean spearman R = 0.88) 5 min post injection (pi). Moreover, positive relationships were found between late tracer uptake (90 min pi) and both k₃ and the net influx rate constant, Ki (mean spearman R = 0.56 and R = 0.86; respectively).CONCLUSION: This study shows the feasibility to extract relevant parameters from voxel-wise pharmacokinetic analysis to be used for preclinical validation of 64Cu-ATSM as a hypoxia-specific PET tracer.",
author = "Fan Li and J{\o}rgensen, {Jesper Tranekj{\ae}r} and Jacob Madsen and Andreas Kjaer",
year = "2015",
month = mar,
day = "27",
doi = "10.3390/diagnostics5020096",
language = "English",
volume = "5",
pages = "96--112",
journal = "Diagnostics",
issn = "2075-4418",
publisher = "MDPI AG",
number = "2",

}

RIS

TY - JOUR

T1 - Pharmacokinetic Analysis of 64Cu-ATSM Dynamic PET in Human Xenograft Tumors in Mice

AU - Li, Fan

AU - Jørgensen, Jesper Tranekjær

AU - Madsen, Jacob

AU - Kjaer, Andreas

PY - 2015/3/27

Y1 - 2015/3/27

N2 - The aim of this study was to evaluate the feasibility to perform voxel-wise kinetic modeling on datasets obtained from tumor-bearing mice that underwent dynamic PET scans with 64Cu-ATSM and extract useful physiological parameters.METHODS: Tumor-bearing mice underwent 90-min dynamic PET scans with 64Cu-ATSM and CT scans with contrast. Irreversible and reversible two-tissue compartment models were fitted to time activity curves (TACs) obtained from whole tumor volumes and compared using the Akaike information criterion (AIC). Based on voxel-wise pharmacokinetic analysis, parametric maps of model rate constants k₁, k₃ and Ki were generated and compared to 64Cu-ATSM uptake.RESULTS: Based on the AIC, an irreversible two-tissue compartment model was selected for voxel-wise pharmacokinetic analysis. Of the extracted parameters, k₁ (~perfusion) showed a strong correlation with early tracer uptake (mean spearman R = 0.88) 5 min post injection (pi). Moreover, positive relationships were found between late tracer uptake (90 min pi) and both k₃ and the net influx rate constant, Ki (mean spearman R = 0.56 and R = 0.86; respectively).CONCLUSION: This study shows the feasibility to extract relevant parameters from voxel-wise pharmacokinetic analysis to be used for preclinical validation of 64Cu-ATSM as a hypoxia-specific PET tracer.

AB - The aim of this study was to evaluate the feasibility to perform voxel-wise kinetic modeling on datasets obtained from tumor-bearing mice that underwent dynamic PET scans with 64Cu-ATSM and extract useful physiological parameters.METHODS: Tumor-bearing mice underwent 90-min dynamic PET scans with 64Cu-ATSM and CT scans with contrast. Irreversible and reversible two-tissue compartment models were fitted to time activity curves (TACs) obtained from whole tumor volumes and compared using the Akaike information criterion (AIC). Based on voxel-wise pharmacokinetic analysis, parametric maps of model rate constants k₁, k₃ and Ki were generated and compared to 64Cu-ATSM uptake.RESULTS: Based on the AIC, an irreversible two-tissue compartment model was selected for voxel-wise pharmacokinetic analysis. Of the extracted parameters, k₁ (~perfusion) showed a strong correlation with early tracer uptake (mean spearman R = 0.88) 5 min post injection (pi). Moreover, positive relationships were found between late tracer uptake (90 min pi) and both k₃ and the net influx rate constant, Ki (mean spearman R = 0.56 and R = 0.86; respectively).CONCLUSION: This study shows the feasibility to extract relevant parameters from voxel-wise pharmacokinetic analysis to be used for preclinical validation of 64Cu-ATSM as a hypoxia-specific PET tracer.

U2 - 10.3390/diagnostics5020096

DO - 10.3390/diagnostics5020096

M3 - Journal article

C2 - 26854145

VL - 5

SP - 96

EP - 112

JO - Diagnostics

JF - Diagnostics

SN - 2075-4418

IS - 2

ER -

ID: 160309787